Loading
Epigenetics and DNA Methylation / Acute Myeloid Leukemia Research · Journal article
Cancers · August 14, 2026
Raises a question worth testing. It does not answer one.
This multi-omics re-analysis of public glioblastoma datasets proposes that decitabine reactivates INPP5D/SHIP1 and attenuates mesenchymal and stem-like programs without broadly reversing the temozolomide-resistance transcriptome. An exploratory 11-gene prognostic signature failed external validation (C-index 0.55), and the therapeutic agent mapping (734 agents) is acknowledged as hypothesis-generating rather than clinically directed; the work supports rationales for preclinical combination studies but provides no evidence ready for clinical translation.
Integrative multi-omics observational study with exploratory prognostic model development and external validation. Glioblastoma transcriptomic and single-cell data from five public GEO datasets (source and eligibility criteria for original studies not specified). Internal validation cohort: TCGA-GBM (n=166). External validation cohort: CPTAC-GBM (n=96). No active patient enrollment or treatment data.. Intervention: Decitabine (DAC), a DNA methyltransferase inhibitor, examined via transcriptomic and epigenetic analysis in silico.. Compared with: Temozolomide-resistant (TMZ-resistant) glioblastoma transcriptome as the baseline state; genome-wide analysis included 11,707 co-detected genes to assess reversal..
DAC reprogrammed 1114–1882 differentially expressed genes per cohort and reactivated 146 direct epigenetic targets INPP5D/SHIP1 identified as top-ranked direct epigenetic-reactivation target Genome-wide reversal analysis across 11,707 genes showed negligible effect (Spearman ρ = 0.073)
Pharmacogenomic catalog (734 agents) is acknowledged as hypothesis-generating; most agents are not GBM-directed and not therapeutic recommendations.
This work is not ready to guide clinical practice. It identifies INPP5D/SHIP1 and mesenchymal attenuation as potential targets and hypothesizes decitabine-combination rationales, but the exploratory prognostic signature does not generalize (external C-index 0.55) and no clinical efficacy data are provided. Preclinical follow-up is warranted to test proposed mechanisms experimentally.
Multi-omics mechanistic study in repositioned datasets with an exploratory prognostic model that fails external validation (C-index 0.55), generating hypotheses for combination therapy rather than providing actionable clinical evidence.
As stated by the source record.
Quoted from the source exactly as published.
This work is not ready to guide clinical practice. It identifies INPP5D/SHIP1 and mesenchymal attenuation as potential targets and hypothesizes decitabine-combination rationales, but the exploratory prognostic signature does not generalize (external C-index 0.55) and no clinical efficacy data are provided. Preclinical follow-up is warranted to test proposed mechanisms experimentally.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background/Objectives: Glioblastoma (GBM) is the most lethal primary brain malignancy in adults, with a median overall survival of approximately 15 months. Temozolomide (TMZ) resistance develops in virtually all patients, and no second-line regimen has improved outcomes over the past two decades. The DNA methyltransferase inhibitor decitabine (DAC) has attracted interest as a chemosensitizer, but whether it directly reverses the TMZ-resistance transcriptome or operates through distinct, complementary mechanisms has not been tested at multi-omics resolution. Methods: We performed an integrative six-layer multi-omics analysis across five public GEO datasets (bulk RNA-seq, EPIC 850K methylation, and 21,676 single cells) re-purposed from studies conducted for unrelated aims, formally tested DAC-mediated reversal of the TMZ-resistance transcriptome across 11,707 genes, mapped pharmacogenomic targets with DGIdb v5, and built an exploratory, hypothesis-generating 11-gene prognostic model internally validated in TCGA-GBM (n = 166) and externally tested in the independent CPTAC-GBM cohort (n = 96). Results: DAC reprogrammed transcription across 1114–1882 differentially expressed genes per cohort and reactivated 146 direct epigenetic targets, identifying INPP5D/SHIP1 as the top-ranked direct epigenetic-reactivation target. Genome-wide reversal analysis across 11,707 co-detected genes showed a negligible effect (Spearman ρ = 0.073), but single-cell analysis revealed significant per-cell attenuation of MES-like and stem-like programs (Δ = −0.071 and −0.135, respectively; both p < 0.001). The 11-gene risk model achieved a Harrell’s C-index of 0.706 (apparent); after correcting for the two-stage gene selection with a full-pipeline bootstrap, the optimism-corrected C-index was 0.63, and external validation in an independent cohort (CPTAC-GBM, n = 96) showed only near-chance discrimination (C-index 0.55), indicating that the signature does not generalize and is exploratory. Pharmacogenomic mapping yielded 734 unique therapeutic agents (230 FDA-approved) across 69 druggable targets after excluding AR. Most of these agents are not GBM-directed, so this catalog-level mapping is hypothesis-generating rather than a set of therapeutic recommendations. Conclusions: DAC does not broadly reverse the TMZ-resistant transcriptome but acts through three complementary mechanisms: epigenetic reactivation of INPP5D/SHIP1, cancer-testis-antigen and type I interferon induction, and per-cell attenuation of mesenchymal–stem-like transcriptional intensity, supporting hypotheses for rationally designed DAC-based combination therapy in TMZ-resistant GBM.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.